Drug evaluation: E-5564. Journal Articles

abstract

• Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological effects of endotoxin-mediated responses caused by bacterial infection, including septic shock.

authors

• Ondiveeran, Hari Kumar
• Fox-Robichaud, Alison

status

• published 

publication date

• June 2004

has subject area

• Animals (MeSH)
• Clinical Trials, Phase I as Topic (MeSH)
• Clinical Trials, Phase II as Topic (MeSH)
• Endotoxemia (MeSH)
• Endotoxins (MeSH)
• Humans (MeSH)
• Lipid A (MeSH)
• Medicinal & Biomolecular Chemistry (Science Metrix)
• Randomized Controlled Trials as Topic (MeSH)
• Sepsis (MeSH)
• Structure-Activity Relationship (MeSH)

published in

• IDrugs: the Investigational Drugs Journal  Journal

keywords

• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Endotoxemia
• Endotoxins
• Humans
• Lipid A
• Randomized Controlled Trials as Topic
• Sepsis
• Structure-Activity Relationship

PubMed ID

• 15197664

start page

• 582

end page

• 590

volume

• 7

issue

• 6